CSPC Wins China’s First Clinical Green Light for In Vivo CAR-T Therapy

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.

CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for SYS6055 Injection, the first in vivo CAR-T therapy cleared for clinical testing in the country. The investigational product uses lentiviral vectors to generate CD19-targeting CAR-T cells directly inside the body, aiming to improve cost, accessibility and treatment speed compared with traditional ex vivo CAR-T therapies. Preclinical data show significant tumor inhibition, a favorable safety profile and time and cost benefits, and the initial approved indication is relapsed or refractory aggressive B-cell lymphoma. The company also sees potential to expand SYS6055 into other CD19-positive B-cell malignancies and autoimmune diseases, positioning CSPC at the forefront of China’s cell therapy innovation and potentially broadening its future oncology and immunology franchise.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company engaged in the research, development and production of innovative therapies. The group focuses on treatments for serious diseases, including oncology, and leverages advanced technologies such as cell and gene therapy to expand its portfolio in the Chinese and global healthcare markets.

Average Trading Volume: 116,550,788

Technical Sentiment Signal: Buy

Current Market Cap: HK$114.3B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.